Who are Gemcitabine with R115777's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gemcitabine-with-r115777.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Gemcitabine with R115777 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Gemcitabine with R115777 (Gemcitabine with R115777) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside analog + farnesyltransferase inhibitor combination. Area: Oncology.

phase 3 Nucleoside analog + farnesyltransferase inhibitor combination Ribonucleotide reductase (gemcitabine); farnesyltransferase (R115777) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Gemcitabine with R115777 (Gemcitabine with R115777) — Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. Gemcitabine is a nucleoside analog that inhibits DNA synthesis, while R115777 is a farnesyltransferase inhibitor that blocks Ras protein activation, together targeting cancer cell proliferation through complementary pathways.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Gemcitabine with R115777 TARGET	Gemcitabine with R115777	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	phase 3	Nucleoside analog + farnesyltransferase inhibitor combination	Ribonucleotide reductase (gemcitabine); farnesyltransferase (R115777)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside analog + farnesyltransferase inhibitor combination class)

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Gemcitabine with R115777 — Competitive Intelligence Brief. https://druglandscape.com/ci/gemcitabine-with-r115777. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab